Beach 1999

Methods	RCT Length of follow‐up: 4 months
Participants	All children living in endemic area Number analysed for primary outcome: 853 Age range/ mean age: 5 to 11 years Inclusion criteria: all children attending 5 schools (grades 1 to 4) Exclusion criteria: haematocrit < 22%
Interventions	Single dose vs placebo Albendazole: 400 mg (SmithKlineBeecham, Philadelphia or generic BeltaPharm, Milan); Ivermectin: 200 to 400 µg/kg (mean 282.7 µg/kg) (Merck, West Point, PA); Albendazole plus ivermectin; Placebo: 250 mg vitamin C.
Outcomes	Height Weight Stool examination for helminth prevalence and intensity (geometric mean) Haematocrit
Notes	Location: Haiti Community category: 3 Results presented in a stratified analysis as per individual infection: disaggregated results not presented; measures of error not given in tables. Source of funding: USAID. Invermectin provided by Philippe Gaxotte (Merck, Inc.) and albendazole by John Horton (SmithKline Beecham).
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table.
Allocation concealment (selection bias)	Unclear risk	No details reported.
Blinding (performance bias and detection bias) All outcomes	Low risk	Participants, provider, and assessors were blind.
Incomplete outcome data (attrition bias) All outcomes	Low risk	29/229 were lost to follow‐up in the placebo group and 25/244 were lost to follow‐up in the albendazole group. Inclusion of all randomized participants (number evaluable/number randomized): 88.4% (853/965).
Selective reporting (reporting bias)	Low risk	All stated outcomes reported.
Other bias	Low risk	No other obvious source of bias.